Alkeon Capital Management LLC Reduces Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Alkeon Capital Management LLC trimmed its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 0.1% in the third quarter, Holdings Channel reports. The institutional investor owned 7,093,822 shares of the biotechnology company’s stock after selling 5,662 shares during the period. Alkeon Capital Management LLC’s holdings in BioCryst Pharmaceuticals were worth $53,913,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in BioCryst Pharmaceuticals by 7.7% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 51,012 shares of the biotechnology company’s stock worth $388,000 after purchasing an additional 3,653 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in shares of BioCryst Pharmaceuticals by 472.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 496,784 shares of the biotechnology company’s stock valued at $3,776,000 after buying an additional 409,938 shares in the last quarter. FMR LLC grew its position in shares of BioCryst Pharmaceuticals by 2.4% in the 3rd quarter. FMR LLC now owns 1,988,389 shares of the biotechnology company’s stock valued at $15,112,000 after buying an additional 46,110 shares during the last quarter. The Manufacturers Life Insurance Company raised its stake in BioCryst Pharmaceuticals by 40.7% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 299,152 shares of the biotechnology company’s stock worth $2,274,000 after acquiring an additional 86,571 shares in the last quarter. Finally, Fisher Asset Management LLC raised its stake in BioCryst Pharmaceuticals by 16.9% during the 3rd quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company’s stock worth $25,369,000 after acquiring an additional 481,359 shares in the last quarter. Hedge funds and other institutional investors own 85.88% of the company’s stock.

Analyst Upgrades and Downgrades

BCRX has been the topic of several research reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a $10.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. StockNews.com upgraded BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, August 6th. Needham & Company LLC reissued a “buy” rating and issued a $14.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. JMP Securities upped their price target on shares of BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the company a “market outperform” rating in a research report on Tuesday, August 6th. Finally, Barclays raised their price objective on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $15.60.

BioCryst Pharmaceuticals Price Performance

BioCryst Pharmaceuticals stock opened at $7.50 on Friday. The business has a 50 day simple moving average of $7.62 and a 200-day simple moving average of $7.28. BioCryst Pharmaceuticals, Inc. has a 12 month low of $4.03 and a 12 month high of $8.88. The stock has a market capitalization of $1.55 billion, a PE ratio of -12.29 and a beta of 1.89.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, hitting analysts’ consensus estimates of ($0.07). The firm had revenue of $117.10 million for the quarter, compared to analysts’ expectations of $113.99 million. The firm’s quarterly revenue was up 35.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.19) EPS. As a group, equities research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.38 EPS for the current year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.